|
Costa Rica HPV Vaccine Trial (IR Travel)
|
Cures Moonshot18I2
|
$89,783
|
N/A
|
N/A
|
|
Costa Rica HPV Vaccine Trial (IR)
|
Cures Moonshot18I3
|
$1,078,107
|
N/A
|
N/A
|
|
IDDA - Partner - CDC
|
NIH-18-013
|
$678,899
|
N/A
|
N/A
|
|
IDDA - Partner - HRSA
|
NIH-18-017
|
$700,000
|
N/A
|
N/A
|
|
IDDA - Partner - CDC
|
NIH-18-018
|
$74,250
|
N/A
|
N/A
|
|
IDDA - Partner - CDC
|
NIH-18-025
|
$127,224
|
N/A
|
N/A
|
|
IGF::OT::IGF Hosting, Maintenance and Professional services for Rave and Medidata Rave Integrated Software
|
261201800033I
|
$5,576,825
|
-, -
|
-
|
|
The purpose of this procurement is to provide strategic planning and support service for the NCI CBITT
|
261201800285P
|
$24,876
|
-, -
|
-
|
|
Electronic Capture of Cancer Claims Data for SEER Program
|
261201800649P
|
$245,000
|
-, -
|
-
|
|
RIESSEARCH, LLC:1164941 [18-046091]
|
261201800744P
|
$22,800
|
-, -
|
-
|
|
IGF::OT::IGF CORE SUPPORT ACTIVITIES: SCIENTIFIC WRITING, TECHNICAL AND LOGISTICAL SUPPORT SERVICES
|
261201700004I
|
$1,200,000
|
BIZZELL, ANTON
|
-
|
|
BUSINESS ANALYST SERVICES TO ACHIEVE A BETTER UNDERSTANDING OF THE BUSINESS PROCESSES OF THE THE FEDERALLY FUNDED RESEARCH AND DEVELOPMENT CENTER (FFRDC) CONTRACTORS BUSINESS SYSTEMS.
|
261201800005A
|
$315,922
|
DURAND, HANK
|
-
|
|
CBCSLC CONTRACT FOR THE NCI CHEMICAL BIOLOGY CONSORTIUM, TO# 1
|
261201500010I
|
$275,323
|
JOHNSON, CHARLES
|
-
|
|
IGF::OT::IGF OPERATION & SUPPORT OF THE CTEP PROTOCOL AND INFORMATION OFFICE (PIO)
|
261201600003C
|
$1,232,875
|
KIERNAN, SHERYL
|
-
|
|
IGF::OT::IGF OTHER FUNCTIONS - IRB MANAGER SOFTWARE. OPTION YEAR TWO
|
261201600195P
|
$168,000
|
LEVERICH, WALDEN
|
-
|
|
IGF::OT::IGF CABEZON GROUP INC:1133841 [16-038312]
|
261201200005I
|
$50,125
|
RATEL, RACHEL
|
-
|
|
TOPIC 373 - PHASE I SBIR - ABZYME THERAPEUTICS, LLC - Moonshot
|
261201800031C
|
$299,999
|
N/A
|
ABZYME THERAPEUTICS, LLC
|
|
IGF::OT::IGF OTHER FUNCTIONS. Healthcare Delivery Research Visiting Scholars Program.
|
261201800642P
|
$51,283
|
-, -
|
ACADEMYHEALTH
|
|
Integrin Regulation of Cancer Progression Through Alternative mRNA Splicing and Nonsense-Medidated Decay (NMD)
|
5R01CA129637-08
|
$375,250
|
DIPERSIO, C MICHAEL
|
ALBANY MEDICAL COLLEGE
|
|
The sequence recognition, structure and function of the IMP family of mRNA binding proteins
|
5F30CA214009-02
|
$49,524
|
BISWAS, JEETAYU
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Signal transduction regulating tumor cell dissemination
|
5R01CA150344-30
|
$396,625
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer
|
5R01CA128943-10
|
$396,625
|
DI CRISTOFANO, ANTONIO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Designing Novel Anti-Cancer Therapeutics: Targeting Methionine Metabolism
|
5F30CA210372-02
|
$49,524
|
FIRESTONE, ROSS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
IGF::OT::IGF IGF::OF::IGF- PHASE III TRIAL OF CARBON ION THERAPY
|
261201500022C
|
$462,158
|
GUHA, CHANDAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Microbial Metabolite Mimics, PXR and Colitis-Induced Colorectal Cancer
|
1R01CA222469-01
|
$549,306
|
MANI, SRIDHAR
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
IGF::OT::IGF MANUFACTURE OF BULK CHEMICALS AND BULK PHARMACEUTICAL INGREDIENTS FOR PRECLINICAL AND CLINICAL STUDIES
|
261201700020C
|
$671,205
|
DENYSENKO, SERGIY
|
ALCHEM LABORATORIES CORPORATION
|
|
IGF::OT::IGF NON-GMP SYNTHESIS OF COMPOUNDS FOR DRUG DEVELOPMENT
|
261201600066C
|
$549,643
|
RUDCHENKO, VLADIMIR
|
ALCHEM LABORATORIES CORPORATION
|
|
IGF::OT::IGF SYNTHESIS OF 30 GRAMS OF THE TARGET COMPOUND, TASK ORDER PERIOD OF PERFORMANCE: 2/28/2018-4/27/2018.
|
261201700007I
|
$96,648
|
ZHANG, MIANJI
|
ALCHEM LABORATORIES CORPORATION
|
|
IGF::OT::IGF SITE LICENSE TO AJCC CANCER STAGING MANUAL, 8TH EDITION, IN SUPPORT OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS), NATIONAL INSTITUTES OF HEALTH (NIH), NATIONAL CANCER INSTITUTE
|
261201800122P
|
$125,000
|
MADERA, MARTIN
|
AMERICAN COLLEGE OF SURGEONS
|
|
IGF::OT::IGF Protocol Information Office (PIO) Support Services
|
261201800045C
|
$630,000
|
-, -
|
ARSERVICES, LTD
|
|
Task Order HHSN26100004 issued for: Task 1 - Operational Support and Configuration Changes and Task ePath Installation.
|
261201500033I
|
$810,970
|
-, -
|
ARTIFICIAL INTELLIGENCE IN MEDICINE, INC
|
|
Dietary Combination For Prevention of Metastatic Renal Cell Carcinoma
|
5R01CA176691-05
|
$341,059
|
LOKESHWAR, VINATA
|
AUGUSTA UNIVERSITY
|
|
Role of heat shock factors (Hsfs) in tumorigenesis
|
5R01CA132640-17
|
$270,000
|
MIVECHI, NAHID
|
AUGUSTA UNIVERSITY
|
|
DEVELOPMENT AND VALIDATION OF NON- MOUSE REAGENTS TO ENABLE PRECLINICAL DEVELOPMENT OF NOVEL THERAPEUTICS - Moonshot
|
261201800041C
|
$299,854
|
N/A
|
AVANTGEN INC
|
|
DACH1/Eya Cell fate determination factor and mammary tumorigenesis
|
5R01CA132115-09
|
$428,056
|
PESTELL, RICHARD
|
BARUCH S. BLUMBERG INSTITUTE
|
|
TOPIC 372 - PHASE I SBIR - BASE PAIR,LLC - Moonshot
|
261201800040C
|
$300,000
|
N/A
|
BASE PAIR BIOTECHNOLOGIES, INC.
|
|
Investigating the mechanisms of CD44s splice isoform in breast cancer metastasis
|
5R01CA182467-06
|
$328,888
|
CHENG, CHONGHUI
|
BAYLOR COLLEGE OF MEDICINE
|
|
A New Lab Based Algorithm for HCC Surveillance in Patients with Cirrhosis
|
5R01CA190776-04
|
$546,636
|
EL-SERAG, HASHEM
|
BAYLOR COLLEGE OF MEDICINE
|
|
Preclinical Analyses of NAD Kinase as a Redox Vulnerability for the Treatment of Pancreatic Cancer
|
5R01CA211176-02
|
$362,569
|
ELSEA, SARAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Breast Cancer Research Training Program
|
1T32CA203690-01A1
|
$194,523
|
FUQUA, SUZANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Computational and Experimental Modeling of Alternative Polyadenylation
|
5R01CA193466-03
|
$361,128
|
LI, WEI
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Novel LGR4 Oncogenic Signaling in Breast Cancer Progression and Metastasis
|
5R01CA204926-02
|
$362,569
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Ruxolitinib for Preventing Breast Cancer in Women on Neuroleptics
|
5R01CA205594-02
|
$362,569
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Novel therapeutics for targeting checkpoint dysfunction in cancer
|
5R01CA203824-02
|
$362,569
|
LIN, WEEI-CHIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Osteogenic Niche Biology in Progression and Endocrine Resistance of Bone Metastases
|
1R01CA221946-01
|
$488,881
|
ROWLEY, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
THE ROLE OF TELOMERASE REGULATORS IN TELOMERE MAINTENANCE AND GENOMIC INSTABILITY
|
5R01CA211653-02
|
$362,569
|
SONGYANG, ZHOU
|
BAYLOR COLLEGE OF MEDICINE
|
|
NCOA6, A Novel Tumor Suppressor of Endometrial Cancer
|
5R01CA193455-03
|
$86,504
|
XU, JIANMING
|
BAYLOR COLLEGE OF MEDICINE
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
5R01CA183984-04
|
$473,915
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Effects of High Fructose Corn Syrup on Intestinal Tumorigenesis
|
1K22CA216036-01
|
$179,877
|
YUN, JIHYE
|
BAYLOR COLLEGE OF MEDICINE
|
|
City of Hope Lymphoma SPORE
|
2P50CA107399-11A1
|
$2,500,000
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|